Macquarie Group LTD Axsome Therapeutics, Inc. Transaction History

Macquarie Group LTD

$83.5 Billion
Q3 2025

A detailed history of Macquarie Group LTD transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 1,084,536 shares of AXSM stock, worth $151 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares

1,084,536

Previous 1,137,748 4.68%

Holding current value

$151 Million

Previous $119 Million 10.9%

% of portfolio

0.16%

Previous 0.15%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$100.39 - $129.29 $5.34 Million - $6.88 Million	-53,212 Reduced 4.68%	1,084,536 $132 Million
Q2 2025 Aug 14, 2025	BUY	$95.65 - $116.49 $15.4 Million - $18.8 Million	161,488 Added 16.54%	1,137,748 $119 Million
Q1 2025 May 15, 2025	BUY	$80.05 - $137.75 $977,650 - $1.68 Million	12,213 Added 1.27%	976,260 $114 Million
Q4 2024 Feb 14, 2025	SELL	$83.08 - $100.49 $2.6 Million - $3.14 Million	-31,240 Reduced 3.14%	964,047 $81.6 Million
Q3 2024 Nov 14, 2024	SELL	$78.93 - $95.84 $6.15 Million - $7.47 Million	-77,955 Reduced 7.26%	995,287 $89.4 Million
Q2 2024 Aug 09, 2024	BUY	$65.72 - $80.5 $24.5 Million - $30 Million	372,832 Added 53.23%	1,073,242 $86.4 Million
Q1 2024 May 14, 2024	BUY	$69.39 - $97.64 $46.7 Million - $65.7 Million	672,886 Added 2444.72%	700,410 $55.9 Million
Q4 2023 Feb 14, 2024	BUY	$57.42 - $83.61 $345,036 - $502,412	6,009 Added 27.93%	27,524 $2.19 Million
Q3 2023 Nov 14, 2023	SELL	$69.25 - $82.21 $1.7 Million - $2.02 Million	-24,576 Reduced 53.32%	21,515 $1.5 Million
Q2 2023 Aug 14, 2023	BUY	$58.41 - $90.35 $1.53 Million - $2.37 Million	26,187 Added 131.57%	46,091 $3.31 Million
Q1 2023 May 15, 2023	BUY	$58.39 - $75.0 $87,468 - $112,350	1,498 Added 8.14%	19,904 $1.23 Million
Q4 2022 Feb 21, 2023	SELL	$39.94 - $79.72 $371,481 - $741,475	-9,301 Reduced 33.57%	18,406 $1.42 Million
Q3 2022 Nov 14, 2022	SELL	$36.06 - $69.85 $235,111 - $455,421	-6,520 Reduced 19.05%	27,707 $1.24 Million
Q2 2022 Aug 15, 2022	SELL	$21.74 - $46.75 $109,721 - $235,947	-5,047 Reduced 12.85%	34,227 $1.31 Million
Q1 2022 May 16, 2022	BUY	$23.7 - $41.39 $307,507 - $537,035	12,975 Added 49.34%	39,274 $1.63 Million
Q4 2021 Feb 11, 2022	BUY	$30.7 - $43.36 $1,657 - $2,341	54 Added 0.21%	26,299 $994,000
Q3 2021 Nov 12, 2021	BUY	$19.91 - $68.26 $32,015 - $109,762	1,608 Added 6.53%	26,245 $865,000
Q2 2021 Aug 13, 2021	BUY	$50.63 - $73.5 $149,155 - $216,531	2,946 Added 13.58%	24,637 $1.66 Million
Q1 2021 May 14, 2021	BUY	$55.91 - $81.44 $153,808 - $224,041	2,751 Added 14.52%	21,691 $1.23 Million
Q4 2020 Feb 16, 2021	BUY	$66.31 - $86.52 $1.18 Million - $1.54 Million	17,772 Added 1521.58%	18,940 $1.54 Million
Q2 2020 Aug 11, 2020	BUY	$49.87 - $98.69 $58,248 - $115,269	1,168 New	1,168 $96,000

Others Institutions Holding AXSM

# of Institutions

414

Shares Held

36.8M

Call Options Held

752K

Put Options Held

567K

View Full List

About Axsome Therapeutics, Inc.

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $5.99B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

More about AXSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account

Macquarie Group LTD Axsome Therapeutics, Inc. Transaction History